Person: SEVEN, GÜLSEREN
11 results
Search Results
Now showing 1 - 10 of 11
Publication Metadata only DELTA HEPATITIS MAY REQUIRE PROLONGED TREATMENT WITH INTERFERON(2011-10-01T00:00:00Z) Kabacam, Gokhan; Yakut, Mustafa; Seven, GÜLSEREN; Karatayli, Senem C.; Nassiri, Camran; Bozkaya, Hakan; Bozdayi, A. Mithat; Idilman, Ramazan; Yurdaydin, Cihan; SEVEN, GÜLSERENPublication Metadata only Assessment of Helicobacter pylori eradication rate of triple combination therapy containing levofloxacin(2011-12-01T00:00:00Z) Seven, GÜLSEREN; Cinar, Kubilay; Yakut, Mustafa; Idilman, Ramazan; Ozden, Ali; SEVEN, GÜLSERENBackground/aims: Owing to its high efficacy, ease of use, perfect adaptation and low complication profile, it is suggested that the triple therapy combination consisting of levofloxacin, amoxicillin and proton pump inhibitor may be an alternative for the first-line and second-line treatment of Helicobacter pylori. The aim of this study is to evaluate the efficacy of the triple therapy regimen containing two different doses of levofloxacin in the first-line eradication treatment. Material and Methods: 110 naive patients with anti Helicobacter pylori treatment indications according to Maastricht III Consensus Report were included to the study. Patients were randomized into two groups as the patients treated with a levofloxacin (500 mg o.i.d), amoxicillin (1 g b.i.d) and proton pump inhibitor (b.i.d) combination for 10 days (Group 1, n=60) and patients treated with a levofloxacin (500 mg b.i.d), amoxicillin (1 g bid) and proton pump inhibitor (b.i.d) combination for 10 days (Group 2, n=50). Eradication rate was assessed at the 6th week of therapy just subsequent to termination of treatment. Results: 110 treatment-naive patients (60 female, mean age: 44.1 +/- 14.7 years) were randomized and all patients completed the study. Helicobacter pylori eradication of the Group I was 60% and in Group 2 was 72.7%. The difference between the two groups was not statistically significant (p=0.427). None of patients experienced severe complication that would lead to discontinuation of therapy. Conclusion: It is observed that the efficacy of the triple therapy combination containing levofloxacin is not within acceptable limits for the first-line Helicobacter pylori eradication.Publication Metadata only Entecavir Treatment of Chronic Hepatitis D(2012-09-01T00:00:00Z) Kabacam, Gokhan; ÖNDER, Fatih Oğuz; Yakut, Mustafa; Seven, GÜLSEREN; Karatayli, Senem C.; Karatayli, Ersin; Savas, Berna; Idilman, Ramazan; Bozdayi, A. Mithat; Yurdaydin, Cihan; SEVEN, GÜLSERENBackground. Hepatitis D virus (HDV) requires hepatitis B surface antigen (HBsAg) to propagate infection and cause disease. Entecavir is a nucleoside analog with potent antiviral efficacy, and in the woodchuck animal model it also decreased hepatitis B virus (HBV) cccDNA and woodchuck surface antigen. The aim of this study was to investigate the efficacy of entecavir in chronic hepatitis D (CHD).Publication Metadata only HBSAG SEROCOVERSION UNDER LAMIVUDINE IN HBEAG-NEGATIVE CHRONIC HEPATITIS B(2010-10-01T00:00:00Z) Seven, GÜLSEREN; Idilman, Ramazan; Bozkus, Yusuf; Cinar, Kubilay; Kabacam, Gokhan; Yakut, Mustafa; Bozdayi, A. Mithat; Yurdaydin, Cihan; SEVEN, GÜLSERENPublication Metadata only IDENTIFICATION OF RISK FACTORS FOR FIBROSIS PROGRESSION IN NON-ALCOHOLIC FATTY LIVER DISEASE(2010-10-01T00:00:00Z) Seval, Guldane; Idilman, Ramazan; Cinar, Kubilay; Seven, GÜLSEREN; Yakut, Mustafa; Kabacam, Gokhan; Evranos, Berna; Savas, Berna; Bahar, Kadir; SEVEN, GÜLSERENPublication Metadata only Characterization of the inactive HBsAG carrier state with 4 years of follow-up(2012-10-01T00:00:00Z) Yakut, Mustafa; Keskin, Onur; Seven, GÜLSEREN; Kabacam, Gokhan; Karatayli, Ersin; Karatayli, Senem C.; Bektas, Mehmet; Bozdayi, A. Mithat; Idilman, Ramazan; Yurdaydin, Cihan; SEVEN, GÜLSERENPublication Metadata only Endoscopic treatment of biliary complications following liver transplantation(2014-04-01T00:00:00Z) Seven, GÜLSEREN; Cinar, Kubilay; Idilman, Ramazan; Tuzuner, Acar; Hazinedaroglu, Selcuk; Karayalcin, Selim; Bahar, Kadir; SEVEN, GÜLSERENBackground/Aims: The aims of the present study were to review biliary complications following liver transplantation in a single-center experience, to identify the factors associated with biliary complications, and to evaluate the success of endoscopic and percutaneous treatment in such patients.Publication Metadata only Manometric assessment of esophageal motor function in patients with primary biliary cirrhosis(2014-03-01T00:00:00Z) Bektas, Mehmet; Seven, GÜLSEREN; Idilman, Ramazan; Yakut, Mustafa; Doganay, Beyza; Kabacam, Gokhan; Ustun, Yusuf; Korkut, Esin; Kalkan, Cagdas; Sahin, Gunay; Cetinkaya, Hulya; Bozkaya, Hakan; Yurdaydin, Cihan; Bahar, Kadir; Cinar, Kubilay; Soykan, Irfan; SEVEN, GÜLSERENIntroduction/aim: Primary biliary cirrhosis is associated with other autoimmune diseases including Sjogren-s syndrome, and scleroderma. Esophageal dysmotility is well known in scleroderma, and Sjogren-s syndrome. The aim of this study is to investigate whether any esophageal motor dysfunction exists in patients with primary biliary cirrhosis.Publication Metadata only OUTCOME OF CHRONIC DELTA HEPATITIS: EXPERIENCE GAINED FROM A LARGE SINGLE CENTER COHORT(2010-10-01T00:00:00Z) Kabacam, Gokhan; ÖNDER, Fatih Oğuz; Seven, GÜLSEREN; Yakut, Mustafa; Bozkaya, Hakan; Bozdayi, A. Mithat; Idilman, Ramazan; Yurdaydin, Cihan; SEVEN, GÜLSERENPublication Metadata only Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir(2013-01-01T00:00:00Z) Karatayli, Ersin; Idilman, Ramazan; Karatayli, Senem C.; Cevik, Emrah; Yakut, Mustafa; Seven, GÜLSEREN; Kabacam, Gokhan; Bozdayi, A. Mithat; Yurdaydin, Cihan; SEVEN, GÜLSERENBackground: Clonal analysis of quasispecies of resistant HBV genomes in patients with entecavir (ETV) resistance receiving lamivudine (3TC) plus adefovir (ADV) rescue therapy has never been performed.